A Propensity-Score Matched Analysis on Outcomes Using Recombinant Activated Factor VII in Pediatric Cardiac Surgery

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 33, Issue 5, 2019, Pages 1269-1275

  Li, Yinan ^a   Zhao, Wei ^a   Luo, Qipeng ^a   Wu, Xie ^a   Ding, Jie ^a   Yan, Fuxia ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

cardiac surgery; congenital heart disease; pediatric; recombinant activated factor VII; refractory bleeding

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEART SURGERY; HUMAN; INTENSIVE CARE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PEDIATRIC SURGERY; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL MORTALITY; CARDIOPULMONARY BYPASS; CHILD; CONGENITAL HEART MALFORMATION; HOSPITAL MORTALITY; INFANT; PRESCHOOL CHILD; TREATMENT OUTCOME; TRENDS;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; FACTOR VIIA; FEMALE; HEART DEFECTS, CONGENITAL; HOSPITAL MORTALITY; HUMANS; INFANT; MALE; POSTOPERATIVE HEMORRHAGE; PROPENSITY SCORE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85061311337     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2018.12.016     Document Type: Article

References (30)

1. Vivacqua, A., Koch, C.G., Yousuf, A.M., et al. Morbidity of bleeding after cardiac surgery: Is it blood transfusion, reoperation for bleeding, or both?. Ann Thorac Surg 91 (2011), 1780–1790.
2. Whitson, B.A., Huddleston, S.J., Savik, K., et al. Bloodless cardiac surgery is associated with decreased morbidity and mortality. J Cardiac Surg 22 (2007), 373–378.
3. Delaney, M., Stark, P.C., Suh, M., et al. Massive transfusion in cardiac surgery: The impact of blood component ratios on clinical outcomes and survival. Anesth Analg 124 (2017), 1777–1782.
4. Turan, A., Yang, D., Bonilla, A., et al. Morbidity and mortality after massive transfusion in patients undergoing non-cardiac surgery. Can J Anaesth 60 (2013), 761–770.
5. Sun, Y., Jin, Z.K., Xu, C.X., et al. Investigation of the current situation of massive blood transfusion in different surgical departments: A large multicenter study in China. Int J Clin Exper Med 8 (2015), 9257–9265.
6. Lisman, T., De Groot, P.G., Mechanism of action of recombinant factor VIIa. J Thromb Haemost 1 (2003), 1138–1139.
7. Butenas, S., Brummel, K.E., Branda, R.F., et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 99 (2002), 923–930.
8. Witmer, C.M., Huang, Y.S., Lynch, K., et al. Off-label recombinant factor VIIa use and thrombosis in children: A multi-center cohort study. J Pediatrics 158 (2011), 820–825 e821.
9. Karkouti, K., Arellano, R., Aye, T., et al. Off-label use of recombinant activated factor VII in surgical and non-surgical patients at 16 Canadian hospitals from 2007 to 2010 (Canadian Registry Report). Can J Anaesth 61 (2014), 727–735.
10. Donovan, P.J., Iedema, J., McLeod, D.S., et al. Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland. ANZ J Surg 83 (2013), 149–154.
11. Andrew, M., Paes, B., Milner, R., et al. Development of the human coagulation system in the full-term infant. Blood 70 (1987), 165–172.
12. Hornykewycz, S., Odegard, K.C., Castro, R.A., et al. Hemostatic consequences of a non-fresh or reconstituted whole blood small volume cardiopulmonary bypass prime in neonates and infants. Paediatr Anaesth 19 (2009), 854–861.
13. Henriksson, P., Varendh, G., Lundstrom, N.R., Haemostatic defects in cyanotic congenital heart disease. Br Heart J 41 (1979), 23–27.
14. Alfirevic, A., Duncan, A., You, J., et al. Recombinant factor VII is associated with worse survival in complex cardiac surgical patients. Ann Thorac Surg 98 (2014), 618–624.
15. Brase, J., Finger, B., He, J., et al. Analysis of outcomes using low-dose and early administration of recombinant activated factor VII in cardiac surgery. Ann Thorac Surg 102 (2016), 35–40.
16. Downey, L., Brown, M.L., Faraoni, D., et al. Recombinant factor VIIa is associated with increased thrombotic complications in pediatric cardiac surgery patients. Anesth Analg 124 (2017), 1431–1436.
17. Karsies, T.J., Nicol, K.K., Galantowicz, M.E., et al. Thrombotic risk of recombinant factor seven in pediatric cardiac surgery: A single institution experience. Ann Thorac Surg 89 (2010), 570–576.
18. Chapman, A.J., Blount, A.L., Davis, A.T., et al. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery. Eur J Cardiothorac Surg 40 (2011), 1314–1318 discussion 1318–9.
19. Uber, W.E., Toole, J.M., Stroud, M.R., et al. Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: Clinical and economic outcomes. J Thorac Cardiovasc Surg 141 (2011), 1469–1477 e1462.
20. Hoffman, M., Monroe, D.M. 3rd, Roberts, H.R., Activated factor VII activates factors IX and X on the surface of activated platelets: Thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 9:Suppl 1 (1998), S61–S65.
21. Friederich, P.W., Levi, M., Bauer, K.A., et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 103 (2001), 2555–2559.
22. He, S., Blomback, M., Jacobsson Ekman, G., et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 1 (2003), 1215–1219.
23. Warren, O.J., Rogers, P.L., Watret, A.L., et al. Defining the role of recombinant activated factor VII in pediatric cardiac surgery: Where should we go from here?. Pediatr Crit Care Med 10 (2009), 572–582.
24. Romagnoli, S., Bevilacqua, S., Gelsomino, S., et al. Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery. Anesth Analg 102 (2006), 1320–1326.
25. Gelsomino, S., Lorusso, R., Romagnoli, S., et al. Treatment of refractory bleeding after cardiac operations with low-dose recombinant activated factor VII (NovoSeven): A propensity score analysis. Eur J Cardiothorac Surg 33 (2008), 64–71.
26. Singh, S.P., Chauhan, S., Choudhury, M., et al. Recombinant activated factor VII in cardiac surgery: Single-center experience. Asian Cardiovasc Thorac Ann 22 (2014), 148–154.
27. Payani, N., Foroughi, M., Dabbagh, A., The effect of intravenous administration of active recombinant factor VII on postoperative bleeding in cardiac valve reoperations; A randomized clinical trial. Anesth Pain Med, 5, 2015, e22846.
28. McQuilten, Z.K., Barnes, C., Zatta, A., et al. Off-label use of recombinant factor VIIa in pediatric patients. Pediatrics 129 (2012), e1533–e1540.
29. Habib, A.M., Comparison of low- and high-dose recombinant activated factor VII for postcardiac surgical bleeding. Indian J Crit Care Med 20 (2016), 497–503.
30. Yank, V., Tuohy, C.V., Logan, A.C., et al. Systematic review: Benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154 (2011), 529–540.